ArticleIn vivo (Athens, Greece)
Effects of Institutional Experience on Plan Quality in Stereotactic Radiotherapy Using HyperArc for Brain Metastases.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Deep-Learning-Based 3D Dose Distribution Prediction for VMAT Lung Cancer Treatment Using an Enhanced UNet3D Architecture with Composite Loss Functions.Bioengineering (Basel, Switzerland) · 2026Article
- Evaluating the trade-off between plan complexity, dosimetric accuracy, and treatment efficiency: Role of aperture shape controller settings in HyperArc for intracranial oligometastases.Precision radiation oncology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimHyperArc (HA) is an automated planning technique enabling single-isocenter brain stereotactic radiotherapy (SRT); however, dosimetric outcomes may be influenced by the planner's expertise. This study aimed to assess the impact of institutional experience on the plan quality of HA-SRT for both single and multiple brain metastases. MATERIALS AND
methodsTwenty patients who underwent HA-SRT for single metastasis between 2020 and 2021 comprised the earlier group, while those treated between 2022 and 2024 constituted the later group. For multiple metastases, 40 patients who received HA-SRT from 2020-2024 were divided into earlier and later treatment groups. Dosimetric parameters including gross tumor volume (GTV) doses (D
resultsThe later group exhibited significantly higher D
conclusionEnhanced dosimetric outcomes in the later group suggested that accumulated experience contributed to improve GTV and brain dose in HA SRT. Institutional experience is important to improve the plan quality for SRT even with automatic planning such as HA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.